Roth Capital Issues Optimistic Outlook for ALUR Earnings

Allurion Technologies Inc. (NYSE:ALUR) – Research analysts at Roth Capital upped their Q3 2025 EPS estimates for shares of Allurion Technologies in a report released on Wednesday, November 13th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.14). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Allurion Technologies’ current full-year earnings is ($0.40) per share. Roth Capital also issued estimates for Allurion Technologies’ Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.54) EPS and FY2026 earnings at ($0.29) EPS.

ALUR has been the subject of a number of other reports. TD Cowen initiated coverage on Allurion Technologies in a research note on Wednesday, October 2nd. They set a “buy” rating and a $2.00 price objective for the company. Chardan Capital lowered shares of Allurion Technologies from a “buy” rating to a “neutral” rating in a research note on Thursday, November 14th. Finally, Roth Mkm started coverage on shares of Allurion Technologies in a research note on Friday, September 6th. They issued a “buy” rating and a $2.00 target price for the company. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $2.88.

Allurion Technologies Stock Performance

Shares of ALUR stock opened at $0.41 on Monday. The firm’s 50 day moving average price is $0.66 and its two-hundred day moving average price is $1.01. The stock has a market cap of $26.37 million, a PE ratio of -0.85 and a beta of -0.37. Allurion Technologies has a 52-week low of $0.31 and a 52-week high of $4.24.

Institutional Investors Weigh In On Allurion Technologies

Several large investors have recently made changes to their positions in the stock. CVI Holdings LLC bought a new stake in Allurion Technologies in the 2nd quarter valued at $520,000. Geode Capital Management LLC lifted its holdings in shares of Allurion Technologies by 40.7% in the third quarter. Geode Capital Management LLC now owns 516,330 shares of the company’s stock valued at $317,000 after purchasing an additional 149,484 shares in the last quarter. Finally, Accredited Investors Inc. boosted its position in shares of Allurion Technologies by 33.3% during the second quarter. Accredited Investors Inc. now owns 50,000 shares of the company’s stock worth $50,000 after buying an additional 12,500 shares during the period. Institutional investors own 21.39% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.